Survival analysis for non-squamous NSCLC patients harbored STK11 or KEAP1 mutation receiving atezolizumab
Xiaoling Shang, Zhenxiang Li, Jian Sun, Chenglong Zhao, Jiamao Lin, Haiyong Wang
Topics & Concepts
AtezolizumabMedicineSTK11OncologyInternal medicineCancerPembrolizumabImmunotherapyColorectal cancerKRASLung Cancer Treatments and MutationsCancer Immunotherapy and BiomarkersMelanoma and MAPK Pathways